HDFC Flexi Cap Fund exits IndusInd Bank and HAL, adds Swiggy in May
HDFC Flexi Cap Fund
, the second-largest
flexi cap fund
by assets under management, made a complete exit from three stocks in May—IndusInd Bank,
Hindustan Aeronautics
(
HAL
), and Indigo Paints—while adding
Swiggy
to its portfolio during the same period.
The fund offloaded approximately 25 lakh shares of
IndusInd Bank
, 15 lakh shares of HAL, and 3.3 lakh shares of
Indigo Paints
during the month. On the other hand, it added 80 lakh shares of Swiggy to its portfolio in May.
Also Read |
Nifty stuck in narrow range. Here's the mutual fund move you need to make now
Best MF to invest
Looking for the best mutual funds to invest? Here are our recommendations.
View
Details
»
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
Get Ozempic, Wegovy or Mounjaro at a low price
Medvi
Get Offer
Undo
The second-largest flexi cap fund increased its stake in 13 stocks in May, including
Cipla
,
State Bank of India
,
JSW Steel
,
ONGC
,
Havells India
, PGCI,
Bajaj Auto
,
Sapphire Foods India
,
Piramal Pharma
,
SBI Life Insurance
,
Bank of Baroda
, and
FSN E-Commerce Ventures
.
The fund added 1.58 crore shares of Bank of Baroda, raising its total holding to 3.20 crore shares in May, up from 1.62 crore in April. It also increased its stake in Oil & Natural Gas Corporation (ONGC) by 1.21 crore shares, taking the total to 2.50 crore shares in May from 1.28 crore in April.
Live Events
Additionally, the fund bought 75 lakh shares of State Bank of India and 63.98 lakh shares of FSN E-Commerce Ventures during the month.
Also Read |
Explained: What all Gen-Z should know about mutual funds
Meanwhile, the fund reduced exposure in 12 stocks, including Delhivery, Ashok Leyland, Mahindra & Mahindra, Bosch,
ITC
, Axis Bank, HCL Technologies, Birlasoft, Tech Mahindra, Kalpataru Projects International, Prestige Estates Projects, and InterGlobe Aviation.
Around 20.28 lakh shares of Prestige Estates were sold from the portfolio, followed by 17.28 lakh shares of Tech Mahindra during the same period. The fund also offloaded 13,135 shares of Bosch in the corresponding time frame.
The exposure in 27 stocks remained unchanged in May, including HDFC Bank, Infosys, Kotak Mahindra Bank, Lupin, The Ramco Cements, Reliance Industries, Tata Steel, Escorts Kubota, L&T, Eicher Motors, Apollo Hospitals Enterprises, ICICI Bank, Cyient, and Bharti Airtel.
HDFC Flexi Cap Fund is an open-ended dynamic equity scheme that invests across large-cap, mid-cap, and small-cap stocks. The investment objective of the fund is to generate capital appreciation/income by predominantly investing in equity and equity-related instruments.
The fund is benchmarked against the Nifty 500 Total Returns Index and is managed by Roshi Jain. Launched on January 1, 1995, the scheme had an AUM of Rs 75,784.48 crore as of May 31, 2025.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
India Gazette
31 minutes ago
- India Gazette
Rural FMCG volume grew thrice urban volume growth in Q4FY25, similar trend likely to continue: Report
New Delhi [India], June 30 (ANI): Driven by increased distribution of freebies and a positive sentiment from good monsoon, rural market in India's fast-moving consumer goods (FMCG) sector continues to outperform urban areas, according to a recent report by Nuvama Institutional Equities. The report stated that rural markets continued to outpace urban areas in the overall FMCG sector. It noted that rural demand is already doing well and remains strong, while urban markets are facing pressure and are likely to stay under strain until the first half of FY26. However, urban demand is expected to start improving from the second half of FY26, the report stated. In terms of volume growth, rural regions have shown remarkable performance. For the fourth consecutive quarter, rural areas have grown more than twice as fast as urban regions. In Q4FY25, rural FMCG volumes grew by 8.4 per cent, while urban volume growth stood at 2.6 per cent, it said. The report also highlighted that the FMCG sector volumes in Q4FY25 saw rural growth being three times higher than urban areas. Initial data for Q1FY26 suggests a similar trend is likely to continue. Overall, the consumer sector grew 11 per cent year-on-year (YoY) by value in Q4FY25, compared to 10.6 per cent YoY in Q3FY25. Pricing growth was reported at 5.6 per cent, while overall volumes expanded by 5.1 per cent YoY, a slight decline from the 7.1 per cent YoY growth recorded in Q3FY25. Despite the positive performance in rural markets, the FMCG sector saw a significant selloff by foreign portfolio investors (FPIs) in the first half of June 2025. According to the report, FMCG recorded the highest outflows of Rs 36.3 billion, after receiving net inflows worth Rs 8.2 billion in May. Until May, the sector witnessed sales worth over Rs 140 billion. The report added that FPIs showed a strong inclination towards rate-sensitive and beta plays, contributing to the withdrawal from FMCG stocks. (ANI)
News18
33 minutes ago
- News18
UP's Much-Awaited Pharma Park All Set To Become A Reality By 2027
Last Updated: With construction underway on over 350 acres in the first phase, the project is expected to catalyse investments worth over Rs 12,000 crore Uttar Pradesh's much-awaited Pharma Park is all set to become a reality by 2027 as the state government begins work on North India's first bulk drug and formulation hub in Lalitpur. With construction underway on over 350 acres in the first phase, the project is expected to catalyse investments worth over Rs 12,000 crore and boost UP's bid to become a national pharmaceutical manufacturing powerhouse. Spearheaded by the Uttar Pradesh State Industrial Development Authority (UPSIDA), the Lalitpur Bulk Drug Pharma Park is part of UP government's move to make the state self-reliant in bulk drug and Active Pharmaceutical Ingredient (API) production, while transforming Bundelkhand into an industrial powerhouse. Spread over 1,472 acres, the park is being developed in phases. Construction work for the first phase, covering 353 acres, is already underway. According to UPSIDA, environmental clearances have been secured, and land allotment to industries has begun. UPSIDA regional manager Sandeep Kumar confirmed that four pharmaceutical companies have submitted applications to set up units within the park. Of these, IJ Pharma and Badariya Pharma have already been allotted plots, while Riddhi Siddhi Pharma and JBJM Pharmaceuticals are in the final stages of the allotment process. 'Contracts with two companies are complete, while documentation for the remaining two is ongoing," Kumar said. The project has already caught the attention of prominent investors. During a recent investment roadshow in Ahmedabad, several pharma companies signed key proposals. UPSIDA CEO Mayur Maheshwari stated that the authority will conduct similar outreach initiatives in Mumbai, Chandigarh, and Hyderabad to attract more pharma players. Maheshwari described the park as a 'state-of-the-art plug-and-play facility" tailored to meet global standards. 'All utilities—electricity, water, waste management—are being designed for 24/7 industrial support. The entire park will be based on Zero Liquid Discharge (ZLD), ensuring that no untreated wastewater leaves the premises," he said. The park's underground utility network will include steam and solvent recovery systems, climate-controlled warehouses, and dedicated logistics corridors. A waste management system with a 3.53 TPD capacity, 33/11 KV sub-stations, and a 75 TPH steam distribution system will be in place to ensure operational efficiency. Safety and support infrastructure are also in focus. Plans include CCTV surveillance, boundary fencing, emergency service centers, and in-house skilling centres for local manpower training. Affordable housing for workers and executives is also under development within the premises. Investor Incentives UPSIDA has rolled out a special industrial land allotment scheme for the pharma park. Plots are priced at Rs 1,914 per square meter, with an additional 2 per cent discount for one-time payment. These rates, according to UPSIDA officials, are highly competitive compared to other pharma hubs in India and are expected to attract significant interest from small and mid-sized pharmaceutical players. 'Infrastructure, regulatory clearances, and affordability are all aligned to offer investors a compelling alternative to Gujarat or Hyderabad," said Maheshwari. The Lalitpur Pharma Park has already begun attracting significant industrial investments. CSL Life Sciences Pvt Ltd has proposed a Rs 200 crore investment to set up two manufacturing units—an IV Bottle Plant and an Oral Solid Dosage (OSD) Plant—spread over 5 to 7 acres. These units are expected to generate employment for over 250 people and become operational within the next two years. In addition, Mediheath Diagnostic Pvt Ltd is establishing a healthcare and diagnostic unit on a 4,200-square-meter plot, while Gaman Irradiation has announced plans to invest Rs 35 crore in a skin treatment and irradiation facility that is projected to create around 150 jobs within 24 to 36 months. Another major entrant, Obmed Pharma, has committed Rs 200 crore for setting up a formulation unit on a five-acre plot, which is expected to employ approximately 100 workers. These early investments signal strong industry confidence in the project and are expected to accelerate momentum as the park gains visibility on the national pharmaceutical landscape. Strong Connectivity The Lalitpur pharma park benefits from excellent multi-modal connectivity. The site is linked via MDR 35B, with NH-44 and NH-539 nearby, and is connected by rail through Tikamgarh and Lalitpur Junction. Air connectivity is facilitated via Khajuraho Airport (125 km away) and Lucknow Airport (385 km away). The proximity to the Jhansi node of the Uttar Pradesh Defence Corridor adds strategic value, as does its alignment with the state's broader goal of becoming a $1 trillion economy. According to Maheshwari, the Lalitpur pharma park is being developed in collaboration with leading national institutions like IIT, DRDO, and private consultancy firm Assystem India Limited, which has experience working on world-class pharma parks in Visakhapatnam. top videos View all 'We're not just matching global standards — we're aiming to surpass them," he said. 'Uttar Pradesh is well-positioned to fill the gap left after tax benefits in Himachal Pradesh ended. With the right policies, infrastructure, and investor confidence, we're ready to take the lead in pharma manufacturing." With construction in full swing, the park is expected to show physical results within two years, potentially transforming Lalitpur into India's premier bulk drug manufacturing hub. First Published: News india UP's Much-Awaited Pharma Park All Set To Become A Reality By 2027
Economic Times
33 minutes ago
- Economic Times
Market Wrap: Sensex drops 452 pts, dragged by financial stocks; Nifty slips below 25,550
Live Events (You can now subscribe to our (You can now subscribe to our ETMarkets WhatsApp channel India's benchmark indices, Sensex and Nifty, ended lower on Monday, the final trading day of the first half of CY25, as profit booking in financial stocks near record highs outweighed gains from improved global risk sentiment. Easing Middle East tensions and a sharp rebound in foreign inflows had bolstered investor confidence, but failed to offset the drag from domestic BSE Sensex declined 452.44 points, or 0.54%, to close at 83,606.46, while the NSE Nifty shed 120.75 points, or 0.47%, to settle at 25, market capitalisation of all listed companies on the BSE shrank by Rs 2,396.6 crore to Rs 461.10 lakh Nifty and Sensex closed about 2.9% and 2.8% below their record highs hit in September, after advancing 2.7% over the past four sessions. For June, the indices gained 3.1% and 2.7%, respectively, marking a fourth straight monthly in financial stocks near record levels offset optimism from easing geopolitical tensions. The Nifty Financial Services index fell 0.6%, with heavyweight HDFC Bank slipping 0.7%.In contrast, broader markets outperformed. The Nifty Midcap 100 rose 0.6% and the Nifty Smallcap 100 added 0.5%. Sigachi Industries plunged 11.5% after a deadly explosion at its Hyderabad facility killed at least eight people and injured over two dozen, according to reports. Torrent Pharma gained 2% after announcing plans to acquire a 46.4% stake in JB Chemicals from private equity firm KKR. JB Chemicals, however, dropped 6.8% as the deal was priced at a discount to its last traded level. Alembic Pharma jumped 7.3% after receiving U.S. FDA approval for an injectable cancer treatment used in ovarian and other cancers.
